SeekingAlpha · Oct 10, 2026
Krystal Biotech: Vyjuvek's Success Is Becoming Its Growth Problem (Downgrade)
Krystal Biotech is downgraded from Buy to Hold as U.S. VYJUVEK sales plateau and growth shifts ex-U.S. Read more on KRYS stock here.
KR
NASDAQ · KRYS
Krystal Biotech, Inc.
Healthcare · Biotechnology
$330.00
Down-$11.85 (-3.59%)
Updated Oct 16, 2026, 7:30 PM
SID Score
6.0/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 7.16B
- P/E ratio
- 35.94
- Dividend yield
- 0.00%
- 52-week range
- $183.03 – $382.54
- Volume
- 288.02K
- Avg. volume
- 324.53K
Price performance · KRYS
KRYS price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 15, 2026
KRYS closed at $330.00 after 21 trading sessions, down 2.58% for the selected period.
- Last close
- $330.00
- Period change
- -2.58%
- Period low
- $321.16
- Period high
- $350.88
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | $332.98 | $338.91 | $328.511 | $330.00 | 288.02K |
| Oct 14, 2026 | $320.41 | $330.965 | $319.01 | $330.69 | 277.54K |
| Oct 13, 2026 | $331.48 | $331.93 | $320.95 | $321.16 | 281.91K |
| Oct 12, 2026 | $329.14 | $334.27 | $328.53 | $332.07 | 168.07K |
| Oct 9, 2026 | $326.55 | $333.56 | $323.87 | $331.61 | 196.96K |
| Oct 8, 2026 | $321.61 | $332.105 | $319.58 | $327.30 | 271.47K |
| Oct 7, 2026 | $324.87 | $330.44 | $320.195 | $324.57 | 354.15K |
| Oct 6, 2026 | $335.16 | $335.16 | $319.61 | $326.81 | 352.14K |
| Oct 5, 2026 | $323.76 | $339.69 | $321.365 | $334.85 | 337.05K |
| Oct 2, 2026 | $326.75 | $329.22 | $320.29 | $322.28 | 425.68K |
| Oct 1, 2026 | $332.51 | $334.52 | $325.22 | $325.31 | 225.74K |
| Sep 30, 2026 | $336.56 | $337.03 | $331.80 | $332.56 | 268.27K |
| Sep 29, 2026 | $334.62 | $338.48 | $331.78 | $335.06 | 225.8K |
| Sep 28, 2026 | $347.00 | $350.00 | $334.01 | $337.08 | 298.93K |
| Sep 25, 2026 | $346.34 | $347.74 | $341.90 | $345.82 | 199.95K |
| Sep 24, 2026 | $341.85 | $345.48 | $336.56 | $344.96 | 222.51K |
| Sep 23, 2026 | $353.84 | $353.84 | $337.58 | $341.75 | 215.95K |
| Sep 22, 2026 | $334.76 | $353.83 | $334.31 | $350.88 | 274.57K |
| Sep 21, 2026 | $339.48 | $341.15 | $332.435 | $333.85 | 210.27K |
| Sep 18, 2026 | $340.00 | $341.35 | $335.50 | $336.67 | 1M |
| Sep 17, 2026 | $340.99 | $343.33 | $335.50 | $338.75 | 280.93K |
Latest KRYS news
The latest Smart Investors Daily articles mentioning KRYS.
Stock researchCompany · Overview
Company
Market Activity
Research & News
KRYS research
Overview
Company profile and research snapshot.
Company profile
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $220.00
- Implied upside
- —
- Analysts
- 18
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 15, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 24, 2026 | Goldman Sachs | Buy | — |
| Sep 21, 2026 | B of A Securities | Buy | — |
| Aug 14, 2026 | RBC Capital | Outperform | — |
| Aug 4, 2026 | Citigroup | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Oct 10, 2026
Krystal Biotech: My Analysis Suggests Stock Has Not Yet Reached Peak Value
Krystal Biotech is rated a 'Buy' due to strong Vyjuvek sales, robust profitability, and a promising pipeline. Read more on KRYS stock here.
Yahoo · Oct 8, 2026
What Krystal Biotech (KRYS)'s VYJUVEK Gene Therapy Momentum Means For Shareholders
Krystal Biotech’s VYJUVEK gene therapy for dystrophic epidermolysis bullosa has already delivered strong commercial traction, generating high revenue and robust gross margins in chronic use. The therapy’s specialized manufacturing process, treatment experience, and recurring revenue model have created a meaningful competitive moat, even as European pricing negotiations and emerging rivals introduce new uncertainties. Next, we’ll explore how VYJUVEK’s high-margin, recurring revenue profile...
Yahoo · Oct 8, 2026
Why Krystal Biotech (KRYS) Is Drawing Fresh Attention
Krystal Biotech (KRYS) is drawing fresh attention after news that its VYJUVEK gene therapy for dystrophic epidermolysis bullosa has gained commercial traction, supported by high revenue, strong gross margins, and recurring treatment demand. Recent trading shows a mixed picture for Krystal Biotech. The share price has eased about 9% over the past month and roughly 13% over the last quarter, yet the year-to-date share price return of 31.45% and 1-year total shareholder return of 73.40% point to...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
